未经评估:全球肥胖人数持续增加,与肥胖相关的并发症增加了每个国家的健康负担。因此,新的减肥药,如胰高血糖素样肽-1受体激动剂(GLP-1RAs),正在引起越来越多的关注。这项研究旨在评估美国成年肥胖患者中4种GLP-1RA减肥的成本效益。
UNASSIGNED:四组接受利拉鲁肽(1.8mgQD)的GLP-1RA,塞马鲁肽(1.0mgQW),杜拉鲁肽(1.5mgQW),或艾塞那肽(10μgBID),和一个非治疗组使用决策树模型进行比较.所有估计的参数都来自已发表的文章。质量调整寿命年(QALYs),成本,采用增量成本-效果比(ICER)作为研究终点.我们用支付意愿(WTP)阈值分析了结果,并进行了确定性和概率敏感性分析。
未经证实:GLP-1RA产生了有效的减肥效果;然而,根据WTP为$195000/QALY的阈值,与无治疗相比,并非所有GLP-1RA均具有成本效益.在4个GLP-1RA中,Semaglutide提供了具有成本效益的战略,ICER为135467美元/QALY。敏感性分析表明,这些结果是可靠的。
未经批准:在4个GLP-1RA中,塞马鲁肽是最具成本效益的肥胖药物。
UNASSIGNED: The number of obese people continues to increase worldwide, and obesity-related complications add to every country\'s health burden. Consequently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are attracting increasing attention. This study sought to assess the cost effectiveness for weight loss of 4 GLP-1RAs in adult patients with obesity in the United States.
UNASSIGNED: Four GLP-1RA groups that received Liraglutide (1.8 mg QD), Semaglutide (1.0 mg QW), Dulaglutide (1.5 mg QW), or Exenatide (10 μg BID), and one no-treatment group were compared using a decision-tree model. All the estimated parameters were derived from published articles. Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) were adopted as the study endpoints. We analyzed the results with the willingness-to-pay (WTP) threshold, and conducted deterministic and probabilistic sensitivity analyses.
UNASSIGNED: The GLP-1RAs produced effective weight-loss results; however, not all the GLP-1RAs were cost effective compared to no treatment based on a WTP threshold of $195000/QALY. Among the 4 GLP-1RAs, Semaglutide provided a cost-effective strategy with an ICER of $135467/QALY. The sensitivity analyses showed that these results are reliable.
UNASSIGNED: Among the 4 GLP-1RAs, Semaglutide was the most cost-effective obesity medication.